Bristol-Myers Squibb Company (NYSE:BMY) is one of the best drug stocks to buy right now. On September 8, BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00.
The analyst attributed the rating to the performance of Cobenfy, the company’s new product, in the market, stating that its growth has been stable with a modest percentage increase in the weekly prescription rates.
However, he added that the growth failed to meet the levels expected by some investors for H2 2025. The revenue estimates for the product in Q3 fall slightly below consensus estimates, supporting the Hold rating.
Similarly, William Blair analyst Matt Phipps maintained a neutral stance on Bristol-Myers Squibb Company on September 5, giving the stock a Hold rating.
The analyst told investors that although Bristol-Myers Squibb Company is exhibiting some advancements, including several promising datasets presented at the 2025 IASLC World Conference on Lung Cancer, concerns persist regarding the effectiveness of the VEGF mechanism in delivering a meaningful survival benefit in a global population of NSCLC patients.
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
